Lincomycin,rational selection of high producing strain and improved fermentation by amino acids supplementation

Based on the report that the introduction of the biosynthetic precursor of lincomycin, propylproline, could increase the production of lincomycin (Bruce et al. in US Patent 3,753,859, 1973), a mutant strain pro10–20, with resistance of feedback suppression of proline (an analog of propylproline) was thus selected and lincomycin production increased by 10%. The addition of three amino acids (l-proline, l-tyrosine, l-alanine) which are the precursors of propylproline to the fermentation medium was found to enhance the accumulation of l-dopa through different pathways and was favorable to lincomycin biosynthesis. The production of lincomycin was increased by 23, 10, 13%, respectively, with the addition of 0.05 g L⁻¹ l-proline at 60 h, 0.005 g L⁻¹ l-tyrosine and 0.1 g L⁻¹ l-alanine directly in the medium.     

林可霉素生物合成的研究进展

林可霉素是林可链霉菌(Streptomyces lincolnensis)产生的林可酰胺类抗生素,它抑制细菌细胞的蛋白质合成,临床上主要用于治疗革兰氏阳性菌引起的感染性疾病。林可霉素生物合成基因簇已被克隆和测序。近年来,围绕林可酰胺和丙基脯氨酸的生物合成、调控等进行了深入研究,其硫化反应取得了突破性成果,本文综述了林可霉素生物合成的新进展。